William Blair began coverage on shares of Envista (NASDAQ:NVST) in a note issued to investors on Monday, The Fly reports. The brokerage set an “outperform” rating on the stock.
Several other equities research analysts also recently weighed in on NVST. Bank of America initiated coverage on Envista in a report on Monday. They set a “neutral” rating for the company. Goldman Sachs Group began coverage on Envista in a report on Monday. They set a “buy” rating and a $33.00 price target for the company. JPMorgan Chase & Co. began coverage on Envista in a research report on Monday. They issued an “overweight” rating and a $32.00 price objective for the company. Credit Suisse Group began coverage on Envista in a research report on Monday. They issued a “neutral” rating and a $30.00 price objective for the company. Finally, Robert W. Baird began coverage on Envista in a research report on Monday. They issued an “outperform” rating and a $33.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $32.50.
Shares of NASDAQ NVST traded up $0.35 during mid-day trading on Monday, hitting $28.28. 119,097 shares of the company were exchanged, compared to its average volume of 1,211,606. Envista has a 1-year low of $25.65 and a 1-year high of $29.73.
In other news, CFO Howard H. Yu purchased 2,000 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was acquired at an average price of $22.00 per share, for a total transaction of $44,000.00. Also, CEO Amir Aghdaei purchased 10,000 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was purchased at an average price of $22.00 per share, with a total value of $220,000.00. Insiders acquired 13,000 shares of company stock valued at $286,000 in the last quarter.
Envista Holdings Corporation manufactures and sells dental products in the United States and internationally. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Ormco, Insignia, AOA, and Spark brands.
Featured Story: Cryptocurrencies
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.